Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2012

01-08-2012 | Endocrine Tumors

Classification of Parathyroid Cancer

Authors: Klaus-Martin Schulte, MD, FRCS, Anthony J. Gill, FRCPA, Marcin Barczynski, MD, Elias Karakas, MD, Akira Miyauchi, MD, W. T. Knoefel, MD, Celestino Pio Lombardi, MD, Nadia Talat, BSc Hons, Salvador Diaz-Cano, FRCPath, Clive S. Grant, MD

Published in: Annals of Surgical Oncology | Issue 8/2012

Login to get access

Abstract

Purpose

Parathyroid cancer is rare and often has a poor outcome. There is no classification system that permits prediction of outcome in patients with parathyroid cancer. This study was designed to validate two prognostic classification systems developed by Talat and Schulte in 2010 (“Clinical Presentation, Staging and Long-term Evolution of Parathyroid Cancer,” Ann Surg Oncol 2010;17:2156–74) derived from a retrospective literature review of 330 patients.

Methods

This study contains 82 formerly unreported patients with parathyroid cancer. Death due to disease was the primary end point, and recurrence and disease-free survival were the secondary end points. Data acquisition used a questionnaire of predefined criteria. Low risk was defined by capsular and soft tissue invasion alone; high risk was defined by vascular or organ invasion, and/or lymph node or distant metastasis. A differentiated classification system further classified high-risk cancer into vascular invasion alone (class II), lymph node metastasis or organ invasion (class III), and distant metastasis (class IV). Statistical analyses included risk analysis, Kaplan-Meier analysis, and receiver–operating characteristic (ROC) analysis.

Results

Follow-up ranged 2–347 months (mean 76 months). Mortality was exclusive to the high- risk group, which also predicted a significant risk of recurrence (risk ratio 9.6; 95% confidence interval 2.4–38.4; P < 0.0001), with significantly lower 5-year disease-free survival (χ2 = 8.7; P < 0.005 for n = 45). The differentiated classification also provided a good prognostic model with an area under the ROC curve of 0.83 in ROC analysis, with significant impairment of survival between classes (98.6%, 79.2%, 71.4%, 40.0%, P < 0.05 between each class).

Conclusions

This study confirms the validity of both classification systems for disease outcome in patients with parathyroid cancer.
Appendix
Available only for authorised users
Literature
1.
Talat N, Schulte K. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010;17:2156–74.PubMedCrossRef
2.
3.
4.
Delellis RA. Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma. Endocr Pathol. 2008;19:221–5.PubMedCrossRef
5.
Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109:1736–41.PubMedCrossRef
6.
Shaha AR, Shah JP. Parathyroid carcinoma: a diagnostic and therapeutic challenge. Cancer. 1999;86:378–80.PubMedCrossRef
7.
8.
Chang YJ, Mittal V, Remine S, et al. Correlation between clinical and histological findings in parathyroid tumors suspicious for carcinoma. Am Surg. 2006;72:419–26.PubMed
9.
Bondeson L, Grimelius L, Delellis RA. World Health Organisation classification of tumours, pathology and genetics: tumour of endocrine organs. Lyon, France: IARC Press, 2004.
10.
Sobin LH, Gospodarowicz MK, Wittekind C; International Union Against Cancer. TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell, 2009.
11.
12.
Carlson D. Parathyroid pathology: hyperparathyroidism and parathyroid tumors. Arch Pathol Lab Med. 2010;134:1639–44.PubMed
13.
Agrawal S, Belghiti J. Oncologic resection for malignant tumors of the liver. Ann Surg. 2011;253:656–65.PubMedCrossRef
14.
Renton SC, Gazet JC, Ford HT, Corbishley C, Sutcliffe R. The importance of the resection margin in conservative surgery for breast cancer. Eur J Surg Oncol. 1996;22:17–22.PubMedCrossRef
15.
Juhlin CC, Nilsson IL, Johansson K, et al. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol. 2010;21:166–77.PubMedCrossRef
16.
Elgoweini M, Chetty R. Hyalinizing parathyroid adenoma and hyperplasia: report of 3 cases of an unusual histologic variant. Ann Diagn Pathol. 2011;15:329–32.PubMedCrossRef
17.
Howell VM, Gill A, Clarkson A, et al. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab. 2009;94:434–41.PubMedCrossRef
18.
Volante M, Bollito E, Sperone P, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology. 2009;55:535–43.PubMedCrossRef
19.
Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol. 2005;16:23–32.PubMedCrossRef
20.
Gao Y, Shimizu M, Yamada S, Ozaki Y, Aso T. The effects of chemotherapy including cisplatin on vitamin D metabolism. Endocr J. 1993;40:737–42.PubMedCrossRef
21.
Ríos A, Rodríguez JM, Acosta JM, et al. Prognostic value of histological and immunohistochemical characteristics for predicting the recurrence of medullary thyroid carcinoma. Ann Surg Oncol. 2010;17:2444–51.PubMedCrossRef
22.
Akslen LA. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer. 1993;72:2680–5.PubMedCrossRef
23.
Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245:366–78.PubMedCrossRef
24.
Dralle H, Machens A. Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract Res Clin Endocrinol Metab. 2008;22:971–87.PubMedCrossRef
25.
Sugitani I, Toda K, Yamamoto N, Sakamoto A, Fujimoto Y. Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country. World J Surg. 2010;34:1265–73.PubMedCrossRef
26.
Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer, 2011.
27.
Birbeck KF, Macklin CP, Tiffin NJ, et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg. 2002;235:449–57.PubMedCrossRef
28.
29.
Wiseman SM, Rigual NR, Hicks WL Jr, et al. Parathyroid carcinoma: a multicenter review of clinicopathologic features and treatment outcomes. Ear Nose Throat J. 2004;83:491–4.PubMed
30.
Schulte KM, Talat N, Miell J, Moniz C, Sinha P, Diaz-Cano S. Lymph node involvement and surgical approach in parathyroid cancer. World J Surg. 2010;34:2611–20.PubMedCrossRef
Metadata
Title
Classification of Parathyroid Cancer
Authors
Klaus-Martin Schulte, MD, FRCS
Anthony J. Gill, FRCPA
Marcin Barczynski, MD
Elias Karakas, MD
Akira Miyauchi, MD
W. T. Knoefel, MD
Celestino Pio Lombardi, MD
Nadia Talat, BSc Hons
Salvador Diaz-Cano, FRCPath
Clive S. Grant, MD
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 8/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2306-6

Other articles of this Issue 8/2012

Annals of Surgical Oncology 8/2012 Go to the issue

Breast Oncology

Nomograms for Predicting the Risk of Arm Lymphedema after Axillary Dissection in Breast Cancer

Urologic Oncology

Decreasing Rates of Lymph Node Dissection During Radical Nephrectomy for Renal Cell Carcinoma

Translational Research and Biomarkers

NDRG2 Is Involved in the Oncogenic Properties of Renal Cell Carcinoma and Its Loss Is a Novel Independent Poor Prognostic Factor After Nephrectomy

Breast Oncology

The Association Between Breast Cancer Prognostic Indicators and Serum 25-OH Vitamin D Levels

Healthcare Policy and Outcomes

Risk Factors for Excess Mortality in the First Year After Curative Surgery for Colorectal Cancer

Breast Oncology

Clinicopathologic Risk Factors for the Local Recurrence of Phyllodes Tumors of the Breast